Phase 2, Phase 3 Recruiting Network
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protoco…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03851445
Sites in Florida: - Mount Sinai Comprehensive Cancer Center at Aventura — Aventura, Florida
- UM Sylvester Comprehensive Cancer Center at Aventura — Aventura, Florida
- UM Sylvester Comprehensive Cancer Center at Coral Gables — Coral Gables, Florida
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach — Deerfield Beach, Florida
- Holy Cross Hospital — Fort Lauderdale, Florida
Phase 2, Phase 3 Recruiting Network
This phase II/III Expanded Lung-MAP treatment trial compares the effect of adding cemiplimab to docetaxel and ramucirumab versus docetaxel and ramucirumab alone in treating patients with non-small cell lung cancer that is stage IV or that …
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06616584
Sites in Florida: - Malcom Randall Veterans Administration Medical Center — Gainesville, Florida
- Moffitt Cancer Center — Tampa, Florida
Phase 3 Recruiting NIH
This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06498635
Sites in Florida: - Moffitt Cancer Center-International Plaza — Tampa, Florida
- Moffitt Cancer Center - McKinley Campus — Tampa, Florida
- Moffitt Cancer Center — Tampa, Florida
Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Florida: - UM Sylvester Comprehensive Cancer Center at Aventura — Aventura, Florida
- Boca Raton Regional Hospital — Boca Raton, Florida
- UM Sylvester Comprehensive Cancer Center at Coral Gables — Coral Gables, Florida
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach — Deerfield Beach, Florida
- UM Sylvester Comprehensive Cancer Center at Doral — Doral, Florida
Phase 2, Phase 3 Recruiting Industry
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates fo…
Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT04613596
Sites in Florida: - GenesisCare USA — Aventura, Florida
- Bay Pines Veterans Affairs Healthcare System — Bay Pines, Florida
- Local Institution - 007-922-A — Bonita Springs, Florida
- Local Institution - 007-922-D — Bradenton, Florida
- Local Institution - 007-922-E — Cape Coral, Florida
Phase 3 Recruiting Industry
The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression greater than or equal to 1% and had cance…
Sponsor: Pfizer
NCT ID: NCT07144280
Sites in Florida: - Cancer Care Centers of Brevard, Inc. — Palm Bay, Florida
- Florida Cancer Affiliates - Panama City — Panama City, Florida
Phase 3 Recruiting Industry
Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
Sponsor: Summit Therapeutics
NCT ID: NCT06767514
Sites in Florida: - Clinical Study Sites — Fort Lauderdale, Florida
- Clinical Study Site — Fort Lauderdale, Florida
- Clinical Study Site — Jacksonville, Florida
- Clinical Study Site — Jacksonville Beach, Florida
- Clinical Study Site — North Venice, Florida
Phase 3 Recruiting Industry
The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if ol…
Sponsor: Eli Lilly and Company
NCT ID: NCT06890598
Sites in Florida: - Boca Raton Regional Hospital — Boca Raton, Florida
- Florida Cancer Specialists - South — Fort Meyers, Florida
- University of Florida - Jacksonville — Jacksonville, Florida
- Miami Cancer Institute at Baptist Health, Inc. — Miami, Florida
- Ocala Oncology Center PL DBA Florida Cancer Affiliates - Ocala — Ocala, Florida
Phase 3 Recruiting Industry
Multicenter, randomized (2:1), open-label phase 3 study in HLA-A2 positive patients with squamous and non-squamous metastatic NSCLC with ICI secondary resistance. Patients will be randomized into 2 arms (randomization 2:1): experimental Ar…
Sponsor: OSE Immunotherapeutics
NCT ID: NCT06472245
Sites in Florida: - Comprehensive Hematology Oncology - Bradenton Clinic — Bradenton, Florida
- Comprehensive Hematology Oncology - Brandon Clinic — Brandon, Florida
- Cancer Specialists of North Florida - Fleming Island — Fleming Island, Florida
- Cancer Specialists of North Florida - Riverside — Jacksonville, Florida
- Cancer Specialists of North Florida Southside — Jacksonville, Florida
Phase 3 Recruiting Industry
This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untr…
Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT06875310
Sites in Florida: - Local Institution - 0694 — Clearwater, Florida
- Cancer Specialists of North Florida — Jacksonville, Florida
- Local Institution - 0696 — Miami, Florida
- Local Institution - 0680 — Ocala, Florida
- Mid Florida Hematology and Oncology Center — Orange City, Florida
Phase 3 Recruiting Industry
The goal of this Phase 3 clinical trial is to study the safety and efficacy of the nextgen anti-CTLA-4 antibody, gotistobart (ONC-392/BNT316), in patients with metastatic non-small cell lung cancer who have disease progressed on anti-PD-1/…
Sponsor: OncoC4, Inc.
NCT ID: NCT05671510
Sites in Florida: - D&H Cancer Research Center LLC - 1153 — Margate, Florida
- Ocala Oncology Center PL - 1102 — Ocala, Florida
- AdventHealth Cancer Institute - 1105 — Orlando, Florida
- Orlando Health - 1130 — Orlando, Florida
- Florida Cancer Specialists -South - 1126 — Sarasota, Florida
Phase 2, Phase 3 Recruiting Industry
This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to adults with extensive-stage small cell lung cancer (ES-SCLC), a fast-growing type of lung cancer that has …
Sponsor: Pfizer
NCT ID: NCT07226999
Sites in Florida: - BRCR Coral Springs — Coral Springs, Florida
- Mid Florida Hematology and Oncology Center — Orange City, Florida
- BRCR Global - Tamarac — Tamarac, Florida
Phase 3 Recruiting Industry
This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) and domvanalimab (AB154) compared with durvalumab plus placebo in adults with lo…
Sponsor: AstraZeneca
NCT ID: NCT05211895
Sites in Florida: - Research Site — Jacksonville, Florida
- Research Site — Orlando, Florida
- Research Site — Saint Augustine, Florida
Phase 3 Recruiting Academic/Other
To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC
Sponsor: University of Texas Southwestern Medical Center
NCT ID: NCT02468024
Sites in Florida: - Boca Raton Regional Hospital — Boca Raton, Florida
Phase 2, Phase 3 Recruiting Industry
This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to his…
Sponsor: BioNTech SE
NCT ID: NCT06712316
Sites in Florida: - Clermont Oncology Center — Clermont, Florida
- Mid Florida Cancer Centers — Orange City, Florida
- Cleveland Clinic Florida - Martin North Hospital — Stuart, Florida
- H. Lee Moffit Cancer center and research institute — Tampa, Florida
- Cleveland Clinic Weston Hospital — Weston, Florida
Phase 3 Recruiting Industry
This study, known as LUNAR-2, aims to investigate the effectiveness and safety of using TTFields, delivered by the NovoTTF-200T device, concomitantly administered with pembrolizumab and platinum-based chemotherapy for patients with advance…
Sponsor: NovoCure GmbH
NCT ID: NCT06216301
Sites in Florida: - Florida Cancer Affiliates - Ocala Oncology — Ocala, Florida
- Moffitt Cancer Center — Tampa, Florida
Phase 2, Phase 3 Recruiting Industry
A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07100080
Sites in Florida: - Local Institution - 0085 — Gainesville, Florida
- Local Institution - 0142 — Pembroke Pines, Florida
Phase 3 Recruiting Industry
Beamion LUNG-3 study evaluates whether zongertinib, an oral HER2-targeted treatment, can improve outcomes compared with standard adjuvant treatment in adults with completely resected Stage II-IIIB non-small cell lung cancer (NSCLC) whose t…
Sponsor: Boehringer Ingelheim
NCT ID: NCT07195695
Sites in Florida: - Mid Florida Hematology and Oncology Center — Orange City, Florida
Phase 3 Recruiting Industry
This is a randomized, two-cohort, open-label, phase 3, clinical trial to compare the efficacy and safety of N-803 plus tislelizumab and docetaxel (cohort A) or prior failed Health Authority-approved antiprogrammed death-1 (PD-1) or anti-pr…
Sponsor: ImmunityBio, Inc.
NCT ID: NCT06745908
Sites in Florida: - Holy Cross Hospital — Fort Lauderdale, Florida
- The Oncology Institute of Hope and Innovation — Fort Lauderdale, Florida
- Moffit Cancer Center — Tampa, Florida
Phase 2, Phase 3 Recruiting Industry
Non-Squamous Non-Small Cell Lung Cancer (NSCLC) remains a leading cause of cancer mortality worldwide, with poor survival prospects for metastatic disease. The purpose of this study is to evaluate the optimized dose, adverse events, and ef…
Sponsor: AbbVie
NCT ID: NCT06236438
Sites in Florida: - Memorial Hospital West /ID# 262221 — Pembroke Pines, Florida
- Bond Clinic /ID# 262611 — Winter Haven, Florida
Phase 3 Recruiting Industry
This is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat sarcoma viral on…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06345729
Sites in Florida: - Mount Sinai Cancer Center ( Site 0137) — Miami Beach, Florida
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier opening with Exablate Model 4000 Type 2.0/2.1 for the treatment of NSCLC brain metastases in patients who are undergoing planned FDA approved,…
Sponsor: InSightec
NCT ID: NCT05317858
Sites in Florida: - Miami Cancer Institute at Baptist Health — Miami, Florida
- Moffitt Cancer Center — Tampa, Florida
Phase 3 Recruiting Industry
Lung cancer is one of the most common forms of cancer. One common type is non-small cell lung cancer (NSCLC). NSCLC happens when abnormal cells in the lungs grow too fast. This can stop the lungs from working normally. This study focuses o…
Sponsor: Takeda
NCT ID: NCT07217301
Sites in Florida: - D & H Cancer Research Center — Margate, Florida
- BRCR Global — Tamarac, Florida
Phase 3 Recruiting Industry
The aim of this Phase 3 study is to evaluate the efficacy of Kinisoquin™ as compared to the placebo in prevention of thromboembolic events in patients with metastatic or locally advanced pancreatic cancer.
Sponsor: Quercis Pharma AG
NCT ID: NCT06861088
Sites in Florida: - Clavis Medical, LLC — Miami Lakes, Florida
Phase 3 Recruiting Industry
This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on the prevention of Cancer-Associated Thrombosis (CAT) in participants. The aim of the study is to see how effective the study drug…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT07410117
Sites in Florida: - Bioresearch Partner- Hialeah Hospital — Hialeah, Florida
- Helios Clinical Research — North Miami Beach, Florida